DesirudinDirect thrombin inhibitor
Desirudin is a recombinant form of hirudin, a protein that inhibits thrombin. Its clinical evidence includes preventing venous clots after hip-replacement surgery, a setting with both substantial clotting and bleeding risks.
What is Desirudin?
Desirudin is a recombinant hirudin anticoagulant. It has been studied for preventing deep-vein thrombosis after hip replacement, a setting where both clot prevention and postoperative bleeding matter. 1 2
How it works
It directly inhibits thrombin, an enzyme central to forming a blood clot. This differs from medicines that primarily block platelet aggregation. 2
Effects studied
Postoperative clot prevention
A hip-replacement trial evaluated deep-vein thrombosis prevention. Clots detected by screening and symptomatic or fatal events are different endpoints.
Evidence: Surgical thromboprophylaxis trial. 1
What does the evidence show?
Hip-replacement thrombosis-prevention trial
Stopping a key clotting enzyme
Desirudin binds thrombin directly, interfering with formation of the fibrin mesh that stabilises a clot. Its action differs from that of heparin, which works through another blood protein. These mechanistic differences can matter clinically, but they do not create a risk-free anticoagulant.
Why hip replacement was studied
Major orthopaedic surgery increases the risk of clots in the deep veins of the legs. The retained randomised trial examined desirudin as prevention in this setting. To interpret the result, we need to know who underwent surgery, which treatment was used for comparison and how the investigators detected clots. 1
Screen-detected clots and symptomatic events
Anticoagulant trials may count clots identified by scheduled imaging as well as symptomatic events. Preventing an imaging-detected clot and preventing a fatal pulmonary embolism are related but different outcomes. A fair comparison should preserve that distinction and include the bleeding caused by treatment.
Kidney function and procedures alter risk
Desirudin exposure is affected by kidney function, while bleeding risk interacts with other medicines and invasive procedures. Spinal or epidural procedures require particular anticoagulation planning. Its product history should be checked separately from the trial evidence before describing it as a current treatment choice in a particular country. 2
Safety & status
Bleeding is the central risk. Kidney function affects clearance, and spinal or epidural procedures require specific precautions because bleeding in that setting can be serious. 2
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Is it a blood thinner or a platelet medicine?
It is an anticoagulant that directly inhibits thrombin; it does not work through the platelet target used by drugs such as eptifibatide. 2
Does a lower scan-detected clot rate mean fewer fatal clots?
Not automatically. Those outcomes need to be reported and assessed separately. 1
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.